Piper Jaffray Initiates Coverage on BioMarin (BMRN) with a Neutral; Current Valuation Assumes Success of GALNS
Tweet Send to a Friend
Piper Jaffray initiates coverage on BioMarin Pharmaceutical (Nasdaq: BMRN) with a Neutral rating. Price target $23.
Piper analyst says, "2010 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says, "2010 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
